Geniposide (GEN), a medical herb, is known for its therapeutic applications in cardiovascular diseases, though its efficacy in treating myocardial ischemia/reperfusion injury (MI/RI) is yet to be fully elucidated. This study is an endeavor to explore the potential protective mechanism of GEN against MI/RI. To simulate the MI/RI condition, the left anterior descending artery was occluded for 30 min, followed by a reperfusion period of 120 min in a rat model. Three dosages (50, 100, or 150 mg/kg) of GEN were intraperitoneally injected to the Sprague-Dawley rats once a day, for seven days before the ligation of the artery. The rats were categorized into sham group, MI/RI group, and three different dosages GEN-treated groups. As the results showed, the pretreatment with GEN mitigated myocardial injury, reduced infarct volume, inhibited apoptosis, enhanced superoxide dismutase activity, and decreased malondialdehyde and myeloperoxidase activity, as well as serum creatine kinase-MB and lactate dehydrogenase levels. Moreover, GEN ameliorated MI/RI by downregulating protein expression of toll-like receptor 4, myeloid differentiation primary response 88, and p-nuclear factor-κB. In conclusion, the pretreatment of GEN may be considered as a potential therapeutic option for MI/RI.

中文翻译：

---

京尼平苷预处理通过 TLR4/NF-κB 通路调节炎症反应，减轻心肌缺血/再灌注损伤。

京尼平苷（GEN）是一种药草，因其在心血管疾病中的治疗应用而闻名，但其治疗心肌缺血/再灌注损伤（MI/RI）的功效尚未完全阐明。本研究旨在探索 GEN 对 MI/RI 的潜在保护机制。为了模拟 MI/RI 条件，在大鼠模型中将左前降支动脉闭塞 30 分钟，然后再灌注 120 分钟。在结扎动脉之前，每天一次向 Sprague-Dawley 大鼠腹膜内注射 3 个剂量（50、100 或 150 mg/kg）的 GEN，持续 7 天。将大鼠分为假手术组、MI/RI组和三个不同剂量GEN治疗组。结果显示，GEN预处理减轻了心肌损伤，减少了梗塞体积，抑制了细胞凋亡，增强了超氧化物歧化酶活性，降低了丙二醛和髓过氧化物酶活性，以及​​血清肌酸激酶-MB和乳酸脱氢酶水平。此外，GEN 通过下调 Toll 样受体 4、骨髓分化初级反应 88 和 p-核因子-κB 的蛋白表达来改善 MI/RI。总之，GEN 预处理可被视为 MI/RI 的潜在治疗选择。